Virbac (VIRP) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
8 Jul, 2026Executive summary
Revenue for H1 2025 reached €738.3 million, up 5.0% year-over-year, with 5.6% organic growth at constant rates and scope, driven by both volume and price increases; Sasaeah acquisition in Japan contributed 2.2 points to growth.
EBIT adjusted was €135 million (18.3% of revenue), down 2.4 points YoY at constant exchange rates, mainly due to temporary and calendar effects, higher inventory write-offs, and production shutdowns.
Net result was €82.2 million, down from €94.9 million in HY24, reflecting EBIT evolution, increased financial costs, and FX impacts.
Strong performance in Americas, Europe, EMEA, and Far East Asia, with Mexico, USA, and India as top contributors; Pacific region declined due to Australia.
New CEO Paul Martingell appointed, effective September 1, 2025; Habib Ramdani returns to CFO and deputy CEO roles.
Financial highlights
Net revenue grew 5.6% at actual rates, with a 7.8% rise at constant exchange rates, excluding the positive impact of the Sasaeah acquisition in Japan.
EBIT adjusted margin was 18.3%, down from 21.4% YoY, mainly due to increased write-offs and temporary site closure for maintenance.
Net debt increased to €201.4 million, mainly due to CapEx, working capital needs, and seasonality; net debt/EBITDA ratio remains significantly below 1.
CapEx nearly doubled YoY to €53.9 million, exceeding €50 million in H1, with full-year 2025 and 2026 expected above €100 million due to industrial transformation projects.
Net free cash flow was -€41.1 million, reflecting higher capex and working capital needs.
Outlook and guidance
Full-year 2025 guidance confirmed: net revenue growth of 4%-6% at constant rates and scope (5%-7% including Sasaeah), EBITDA margin around 16% at constant FX, and net debt evolution as previously guided.
Targeting 20% EBIT adjusted margin by 2030, with no change to this ambition.
Sasaeah acquisition expected to add 1 point to 2025 growth and be neutral on EBITA ratio.
Cash position projected to improve by €80 million in 2025, excluding acquisitions.
Moderate impact anticipated from US customs tariffs, with most US revenue shifting to local production.
Latest events from Virbac
- H1 2026 revenue rose 7.4% at CERS, with strong growth across all segments and regions.VIRP
Q2 2026 TU20 Jul 2026 - 13.6% revenue growth, record profit, and strong margin expansion in 2024.VIRP
H2 20249 Jul 2026 - 7.9% organic revenue growth, 16.3% EBIT margin, and strong cash flow drive 2026 outlook.VIRP
H2 20258 Jul 2026 - Q1 2026 revenue rose 7.7% at CERS, driven by double-digit North America and Supercharge growth.VIRP
Q1 2026 TU16 Apr 2026 - Revenue up 15.1% and net income up 26.2% in H1 2024, driven by organic growth and acquisitions.VIRP
H1 202417 Mar 2026 - 2025 revenue rose 7.9% at constant rates, with 2026 growth and margin outlook boosted by acquisitions.VIRP
Q4 2025 TU19 Jan 2026 - Q3 revenue up 12.5% at constant rates; full-year growth guidance raised to 5.5%-7.5%.VIRP
Q3 2025 TU16 Oct 2025 - H1 2025 revenue rose 5.6% at constant exchange rates and scope, led by companion animal growth.VIRP
H1 2025 TU17 Jul 2025 - Q1 2025 revenue up 8.5% to €375.2M; 2025 growth outlook 4–6% at constant exchange rates.VIRP
Q1 2025 TU6 Jun 2025